Paul Lloyd
Overview
Explore the profile of Paul Lloyd including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
2374
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sjostrom M, Zhao S, Levy S, Zhang M, Ning Y, Shrestha R, et al.
Cancer Res
. 2022 Oct;
82(21):3888-3902.
PMID: 36251389
Significance: In prostate cancer, 5-hydroxymethylcytosine delineates oncogene activation and stage-specific cell states and can be analyzed in liquid biopsies to detect cancer phenotypes. See related article by Wu and Attard,...
2.
Lloyd P, Hong A, Furrer M, Lee E, Dev H, Coret M, et al.
World J Urol
. 2021 Oct;
40(1):119-126.
PMID: 34599350
Purpose: To describe and compare differences in peri-operative outcomes of robot-assisted (RA-RPLND) and open (O-RPLND) retroperitoneal lymph node dissection performed by a single surgeon where chemotherapy is the standard initial...
3.
Guler G, Ning Y, Ku C, Phillips T, McCarthy E, Ellison C, et al.
Nat Commun
. 2020 Oct;
11(1):5270.
PMID: 33077732
Pancreatic cancer is often detected late, when curative therapies are no longer possible. Here, we present non-invasive detection of pancreatic ductal adenocarcinoma (PDAC) by 5-hydroxymethylcytosine (5hmC) changes in circulating cell...
4.
Chen W, Aggarwal R, Zhang L, Zhao S, Thomas G, Beer T, et al.
Eur Urol
. 2019 Apr;
76(5):562-571.
PMID: 30928160
Background: Metastatic castration-resistant prostate cancer (mCRPC) is the lethal form of the disease. Several recent studies have identified genomic alterations in mCRPC, but the clinical implications of these genomic alterations...
5.
Aggarwal R, Quigley D, Huang J, Zhang L, Beer T, Rettig M, et al.
Mol Cancer Res
. 2019 Mar;
17(6):1235-1240.
PMID: 30918106
Therapeutic resistance in metastatic castration-resistant prostate cancer (mCRPC) can be accompanied by treatment-emergent small-cell neuroendocrine carcinoma (t-SCNC), a morphologically distinct subtype. We performed integrative whole-genome and -transcriptome analysis of mCRPC...
6.
Quigley D, Dang H, Zhao S, Lloyd P, Aggarwal R, Alumkal J, et al.
Cell
. 2018 Oct;
175(3):889.
PMID: 30340047
No abstract available.
7.
Lu E, Thomas G, Chen Y, Wyatt A, Lloyd P, Youngren J, et al.
J Natl Compr Canc Netw
. 2018 Aug;
16(8):933-937.
PMID: 30099369
PARP inhibition is a promising therapeutic strategy for the treatment of men with metastatic castration-resistant prostate cancer whose tumors harbor homologous recombination DNA repair gene alterations. However, questions remain for...
8.
Quigley D, Dang H, Zhao S, Lloyd P, Aggarwal R, Alumkal J, et al.
Cell
. 2018 Jul;
174(3):758-769.e9.
PMID: 30033370
While mutations affecting protein-coding regions have been examined across many cancers, structural variants at the genome-wide level are still poorly defined. Through integrative deep whole-genome and -transcriptome analysis of 101...
9.
Aggarwal R, Huang J, Alumkal J, Zhang L, Feng F, Thomas G, et al.
J Clin Oncol
. 2018 Jul;
36(24):2492-2503.
PMID: 29985747
Purpose The prevalence and features of treatment-emergent small-cell neuroendocrine prostate cancer (t-SCNC) are not well characterized in the era of modern androgen receptor (AR)-targeting therapy. We sought to characterize the...
10.
Wyatt A, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, et al.
J Natl Cancer Inst
. 2017 Dec;
109(12).
PMID: 29206995
Background: Real-time knowledge of the somatic genome can influence management of patients with metastatic castration-resistant prostate cancer (mCRPC). While routine metastatic tissue biopsy is challenging in mCRPC, plasma circulating tumor...